ESR1 and neoplasm: We hypothesized that tumours exhibiting exceptionally high ER expression (≥90%) represent a subset with maximal endocrine sensitivity, which may, in turn, translate to a superior response to the synergistic blockade of both the ER pathway and the cell cycle via CDK4/6 inhibitors.